Тромбоз, гемостаз и реология

Tromboz, Gemostaz I Reologiya
scientific and practical journal

ISSN 2078–1008 (Print); ISSN 2687-1483 (online)
2026, Miscellaneous
2026

Expert Council Resolution «Unresolved issues in the diagnosis and treatment of adult patients with hemophilia A. Analysis of clinical trials results of coagulation factor VIII with ultra-prolonged half-life (INN: efanesoctocog alfa) in the new concept of normalized hemostasis» 14.11.2025, Moscow

Miscellaneous
Nadezhda I. Zozulya
National Medical Research Center for Hematology, Ministry of Health of the Russian Federation 4 Novy Zykovsky Proezd, Moscow 125167, Russia
Pavel A. Zharkov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of the Russian Federation; 1 Samora Machel Str., Moscow 117198, Russia
Tatiana A. Andreeva
City Center for the Treatment of Hemophilia Patients, Polyclinic No. 37; 6 liter A, Gorokhovaya Str., Saint Petersburg 191186, Russia
Andrey N. Mamaev
Altai Branch of the National Medical Research Center for Hematology, Ministry of Health of the Russian Federation; 1 Lyapidevskogo Str., Barnaul 656045, Russia
Tatyana Yu. Polyanskaya
National Medical Research Center for Hematology, Ministry of Health of the Russian Federation 4 Novy Zykovsky Proezd, Moscow 125167, Russia
Vitaly E. Soldatenkov
Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency; 16 2-ya Sovetskaya Str., Saint Petersburg 191024, Russia
Inna N. Lavrentyeva
Morozov Children’s City Clinical Hospital, Moscow City Health Department; 1/9 4th Dobryninsky Lane, Moscow 119049, Russia

Keywords

hemophilia A
normalized hemostasis
efanesoctocog alfa
FVIII
bleeding
  Full Text

Abstract

Summary. At the Expert Council meeting held in Moscow on October 14, 2025, the implementation of a new concept of “normalized hemostasis” was discussed. This concept involves maintaining FVIII activity ≥ 40% over an extended period in patients with hemophilia A, consistent with current international recommendations. A new factor therapy drug with an ultra-prolonged half-life enables sustained FVIII activity for most of the week after injection, which may help some patients prevent disease complications and reduce the risk of subsequent disability.

For citation: Zozulya N.I., Zharkov P.A., Andreeva T.A., Mamaev A.N., Polyanskaya T.Yu., Soldatenkov V.E., Lavrentyeva I.N. Expert Council Resolution «Unresolved issues in the diagnosis and treatment of adult patients with hemophilia A. Analysis of clinical trials results of ultra-prolonged half-life coagulation factor VIII (INN: efanesoctocog alfa) in the new concept of normalized hemostasis». Tromboz, gemostaz i reologiya. 2026;(1):108–111. (In Russ.).